| 摘要 |
The medicament comprises, as active principal, a melarsomine dihydrochloride preparation having a purity between 98.5 and 100%. The process for obtaining this preparation is set out essentially as follows: - Stage 1, trichlorotriazine (TCT) is converted to diaminochlorotriazine (DCT) in aqueous ammonia medium; - Stage 2, the DCT is converted to melarsenacid hydrochloride (MAH) in the presence of arsanilic acid; - Stage 3, the MAH is reduced to melarsenoxide dihydrate; and - Stage 4, the melarsenoxide dihydrate is converted to melarsomine dihydrochloride in the presence of cysteamine hydrochloride. In each stage, there is obtained a purified preparation of the corresponding intermediate product or final product in Stage 4. <IMAGE>
|
